Fecal microbiota transplantation ( DrugBank: - )


5 diseases
IDDisease name (Link within this page)Number of trials
2Amyotrophic lateral sclerosis1
66IgA nephropathy1
94Primary sclerosing cholangitis1
96Crohn disease9
97Ulcerative colitis31

2. Amyotrophic lateral sclerosis


Clinical trials : 645Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

66. IgA nephropathy


Clinical trials : 275Drugs : 258 - (DrugBank : 82) / Drug target genes : 36 - Drug target pathways : 140 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

94. Primary sclerosing cholangitis


Clinical trials : 148Drugs : 118 - (DrugBank : 39) / Drug target genes : 18 - Drug target pathways : 141 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

96. Crohn disease


Clinical trials : 2,442Drugs : 1,278 - (DrugBank : 248) / Drug target genes : 142 - Drug target pathways : 209 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries

97. Ulcerative colitis


Clinical trials : 2,630Drugs : 1,459 - (DrugBank : 265) / Drug target genes : 144 - Drug target pathways : 202 
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries